GenSight Biologics Commences Patient Treatment Under French Early Access Program

The 15-20 National Hospital and GenSight Biologics have announced the treatment of the first patients under the French Named Patient Early Access Program (AAC) for LUMEVOQ. LUMEVOQ, also known as GS010, is a gene therapy specifically designed to target neurodegenerative diseases of the retina. This initiative allows patients to access innovative treatments within a specialized regulatory framework in France prior to final marketing authorization. The commencement of treatment marks a significant operational milestone for the biotech firm, demonstrating progress in its clinical and regulatory roadmap. GenSight Biologics is currently listed on Euronext Paris under the ticker symbol SIGHT. Market observers view this development as a positive step toward potential early revenue generation and broader commercialization efforts.